ABCL635 Meets Phase 2 Menopause Endpoints
AbCellera reported that a single 600 mg subcutaneous dose of ABCL635, an antibody antagonist of the neurokinin-3 receptor, met both Phase 2 primary endpoints in moderate-to-severe menopausal vasomotor symptoms. At week four, participants had…
